WUHU, China, Oct. 7, 2025 /PRNewswire/ — From 17 to 21 October, guided by the spirit of “With Creating With Love”, 2025 Chery International User Summit will open in Wuhu as scheduled.

As a world-class green and intelligent mobility enterprise, Chery Group will, over five days, redefine industrial value benchmarks and present a comprehensive vision of the future ecosystem — founded on human–machine collaboration, user co-creation, and ecological sharing.

A Trusted Intelligent Assistant — AiMOGA Redefines Human–Machine Collaboration

One of the highlights of the conference will be Chery Group’s breakthrough in robotics.

The much-anticipated AiMOGA robot will make its debut, demonstrating multimodal environmental perception, autonomous navigation, dexterous manipulation, and specialised Q&A capabilities powered by Chery Group’s proprietary AI model.

This represents more than a display of technology — it symbolises how Chery Group’s automotive DNA empowers the robotics industry.

Drawing on decades of expertise in precision manufacturing, quality management, and system integration, Chery Group is introducing automotive-grade standards into the field of service robotics, driving the transformation from laboratory innovation to scalable commercialisation.

At the event, robots will act as intelligent guides interacting naturally with participants. The Robot Dog Challenge will also energise the venue, offering a glimpse into a future where robots become trusted intelligent companions woven seamlessly into daily life.

17.72 Million “Invisible Product Managers” Co-Create and Drive the Evolution of the Ecosystem

At the heart of the conference lies the concept of user sovereignty. Chery Group’s 17.72 million global users are its most valuable ecological assets — the “invisible product managers” who now take centre stage.

At The Dream Drive, Created for You (KOC Forum), users will share insights on brand development, products, and ownership benefits, co-defining Chery’s future direction.

During the automotive long-distance tests and performance events, participants will experience flagship models from CHERY, EXEED, OMODA&JAECOO, iCAUR, LEPAS and LUXEED, tackling complex driving conditions while generating authentic user data that drives continuous product refinement.

Through Chery Brand Factory Visits, participants will explore how Chery’s intelligent manufacturing turns co-creation ideas into precise industrial reality.

This evolution marks Chery’s shift from feedback collection to a two-way partnership — an open, shared ecosystem forming a community of shared value and future between the brand and its users.

More than Cars — Co-Building a Better Ecological Future

In terms of energy strategy, Chery Group will unveil its new-generation Super Hybrid technology, once again setting the industry’s benchmark for energy efficiency and offering greener, more powerful driving experiences.

Yet this is only one dimension of Chery’s vision for intelligent energy. Through experiences such as Ride Green Life, participants will feel how technology and nature can coexist in harmony.

At the same time, Chery Group will continue to collaborate with global partners, including UNICEF, to address international ecological protection — elevating sustainability from corporate responsibility to a shared global action.

2025 Chery International User Summit stands as a profound statement: An open, symbiotic and intelligent new era of mobility is emerging. Human–machine collaboration, user co-creation and ecological sharing will define the future of travel.

This October, from Wuhu to the world, the conference will ignite a celebration of ideas and technology — reshaping the global value landscape of the automotive industry.

NEW YORK, Oct. 7, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on October 7th

• Equities are little changed this morning after stocks kicked off the week in the green. The S&P 500 closed at another record high while the Russell 2000 also surged to a record.
• Intercontinental Exchange (NYSE: ICE) has announced a strategic investment of up to $2 billion into prediction platform Polymarket. This will allow ICE to distribute Polymarket’s event-driven data to a global institutional audience for the first time.
• ICE Chairman and CEO Jeff Sprecher said of the deal, “our investment blends ICE with a forward-thinking, revolutionary company pioneering change within decentralized finance. There are opportunities across markets which ICE together with Polymarket can uniquely serve.”
• Canva is bringing its world tour to New York City. The design software company will be in Herald Square today as it aims to train a million new users on the platform in 30 days.

Opening Bell
The New York Rangers celebrate the start of the franchise’s Centennial Season

Closing Bell
Service Academy Women celebrates 50 years of enrollment at US Federal Service Academies

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2790481/NYSE_Market_Update_October_7.mp4

WUHU, China, Oct. 7, 2025 /PRNewswire/ — From 17 to 21 October, guided by the spirit of “With Creating With Love”, 2025 Chery International User Summit will open in Wuhu as scheduled.

As a world-class green and intelligent mobility enterprise, Chery Group will, over five days, redefine industrial value benchmarks and present a comprehensive vision of the future ecosystem — founded on human–machine collaboration, user co-creation, and ecological sharing.

A Trusted Intelligent Assistant — AiMOGA Redefines Human–Machine Collaboration

One of the highlights of the conference will be Chery Group’s breakthrough in robotics.

The much-anticipated AiMOGA robot will make its debut, demonstrating multimodal environmental perception, autonomous navigation, dexterous manipulation, and specialised Q&A capabilities powered by Chery Group’s proprietary AI model.

This represents more than a display of technology — it symbolises how Chery Group’s automotive DNA empowers the robotics industry.

Drawing on decades of expertise in precision manufacturing, quality management, and system integration, Chery Group is introducing automotive-grade standards into the field of service robotics, driving the transformation from laboratory innovation to scalable commercialisation.

At the event, robots will act as intelligent guides interacting naturally with participants. The Robot Dog Challenge will also energise the venue, offering a glimpse into a future where robots become trusted intelligent companions woven seamlessly into daily life.

17.72 Million “Invisible Product Managers” Co-Create and Drive the Evolution of the Ecosystem

At the heart of the conference lies the concept of user sovereignty. Chery Group’s 17.72 million global users are its most valuable ecological assets — the “invisible product managers” who now take centre stage.

At The Dream Drive, Created for You (KOC Forum), users will share insights on brand development, products, and ownership benefits, co-defining Chery’s future direction.

During the automotive long-distance tests and performance events, participants will experience flagship models from CHERY, EXEED, OMODA&JAECOO, iCAUR, LEPAS and LUXEED, tackling complex driving conditions while generating authentic user data that drives continuous product refinement.

Through Chery Brand Factory Visits, participants will explore how Chery’s intelligent manufacturing turns co-creation ideas into precise industrial reality.

This evolution marks Chery’s shift from feedback collection to a two-way partnership — an open, shared ecosystem forming a community of shared value and future between the brand and its users.

More than Cars — Co-Building a Better Ecological Future

In terms of energy strategy, Chery Group will unveil its new-generation Super Hybrid technology, once again setting the industry’s benchmark for energy efficiency and offering greener, more powerful driving experiences.

Yet this is only one dimension of Chery’s vision for intelligent energy. Through experiences such as Ride Green Life, participants will feel how technology and nature can coexist in harmony.

At the same time, Chery Group will continue to collaborate with global partners, including UNICEF, to address international ecological protection — elevating sustainability from corporate responsibility to a shared global action.

2025 Chery International User Summit stands as a profound statement: An open, symbiotic and intelligent new era of mobility is emerging. Human–machine collaboration, user co-creation and ecological sharing will define the future of travel.

This October, from Wuhu to the world, the conference will ignite a celebration of ideas and technology — reshaping the global value landscape of the automotive industry.

• Over 2,000 global industry and government leaders will attend the second edition of the International MICE Summit (IMS25) in Riyadh, reinforcing Saudi Arabia’s position as one of the fastest-growing business events destinations globally.
• The event builds upon the success of the inaugural 2024 IMS, which attracted more than 1,700 attendees from 25 countries, as Saudi Arabia prepares to host Expo 2030 and the 2034 World Cup.

RIYADH, Saudi Arabia, Oct. 7, 2025 /PRNewswire/ — The International MICE Summit (IMS25) will return to Riyadh during 26–27 November 2025, bringing together more than 2,000 global leaders to unlock growth across the Meetings, Incentives, Conferences and Exhibitions (MICE) industry. Hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), IMS25 will provide attendees with unparalleled access to the world’s fastest-growing major events destination. Aligned with Vision 2030’s goals of economic diversification and human capability development, IMS25 showcases how business events drive cross-sector innovation and sustainable growth. Saudi Arabia is experiencing unprecedented growth in the MICE sector, as the Kingdom invests across the ecosystem in preparation for Expo 2030 and the 2034 Football World Cup.

His Excellency Fahd Al-Rasheed, IMS host and Chairman of Saudi Conventions & Exhibitions General Authority (SCEGA)

Following the resounding success of its inaugural edition in 2024, which attracted more than 1,700 attendees, 140 speakers and moderators from more than 25 countries, IMS25 is set to further cement its position as the global convening force under the theme ‘Public – Private Collaboration: Fueling MICE Growth’.

“Vision 2030 is delivering an unprecedented era of opportunity for the events industry, creating new experiences, opportunities and destinations as Saudi Arabia welcomes the world,” said IMS host and Chairman of SCEGA, His Excellency Fahd Al-Rasheed. “By bringing together leaders, event investors and decision-makers, IMS25 will drive collaboration that delivers connectivity, innovation, and growth across the Kingdom and the global MICE industry.”

“IMS25 builds upon the success of the inaugural Summit last year, deepening partnerships and ensuring this sector can realize the unprecedented opportunities before us, defining new models for growth and value. The business events sector alone has grown by 44% in the past five years, underscoring its pivotal role in the Kingdom’s economic diversification.”

As the fastest-growing business events destination in the G20, Saudi Arabia’s giga-projects, world-class infrastructure investments, and bold vision are generating unprecedented growth opportunities, approximately 17,000 events taking place every year. The Kingdom welcomed a record-breaking 115.9 million tourists in 2024, with a 19% year-on-year increase in visitor spending by international visitors and an 11% overall growth in total tourism spending.

The two-day IMS25 program will feature Ministers, private sector CEOs and commercial announcements in a range of settings, including innovation clusters, a future MICE leaders’ platform, and a celebration gala dinner. Registration is now open at www.internationalmicesummit.com

About the International MICE Summit

The International MICE Summit (IMS) gathers global leaders from the Meetings, Incentives, Conferences, and Exhibitions (MICE) sector, as well as professionals, and organizations from across event-based industries including tourism, culture, sports and entertainment. Hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), IMS25 provides a platform to connect with the world’s newest destinations, decision-makers and innovations to shape the next decade of industry growth. IMS25 follows the resounding success of the inaugural IMS edition in 2024, which attracted 1,700+ attendees, 140 speakers and moderators, and representation from 25 countries.

For more information or to register for the event, visit:

Website – www.internationalmicesummit.com 

Twitter/X – https://x.com/ims_summit 

LinkedIn – https://www.linkedin.com/company/ims-summit/ 

YouTube – https://youtube.com/@ims.summit?si=G06nYTaOUWer-OKq 

About the Saudi Conventions & Exhibitions General Authority (SCEGA)

The Saudi Conventions & Exhibitions General Authority (SCEGA) is the official body overseeing the development and regulation of Saudi Arabia’s exhibitions and conventions sector. Established by Royal Decree in 2018, SCEGA aims to strengthen the sector’s economic impact by setting strategic policies, issuing licenses, promoting Saudi Arabia as a premier MICE destination, and fostering investment in line with global standards. Through collaboration with national and international stakeholders, SCEGA works to enhance sector growth, support talent development, and create opportunities for showcasing the Kingdom’s unique identity on the world stage.

Coming this Fall to IBM Z, LinuxONE and Power, IBM Spyre Accelerator Enables Enterprises to Scale Generative and Agentic AI Workloads

ARMONK, N.Y., Oct. 7, 2025 /PRNewswire/ — IBM (NYSE: IBM) today announced the upcoming general availability of the IBM Spyre Accelerator, an AI accelerator enabling low-latency inferencing to support generative and agentic AI use cases while prioritizing the security and resilience of core workloads. Earlier this year, IBM announced the Spyre Accelerator would be available in IBM z17, LinuxONE 5, and Power11 systems. Spyre will be generally available on October 28 for IBM z17 and LinuxONE 5 systems, and in early December for Power11 servers.

IBM Telum Spyre Chip

Today’s IT landscape is changing from traditional logic workflows to agentic AI inferencing. AI agents require low-latency inference and real-time system responsiveness. IBM recognized the need for mainframes and servers to run AI models along with the most demanding enterprise workloads without compromising on throughput. To address this demand, clients need AI inferencing hardware that supports generative and agentic AI while maintaining the security and resilience of core data, transactions, and applications. The accelerator is also built to enable clients to keep mission-critical data on-prem to mitigate risk while addressing operational and energy efficiency.

The IBM Spyre Accelerator reflects the strength of IBM’s research-to-product pipeline, combining breakthrough innovation from the IBM Research AI Hardware Center with enterprise-grade development from IBM Infrastructure. Initially introduced as a prototype chip, Spyre was refined through rapid iteration, including cluster deployments at IBM’s Yorktown Heights campus, and with collaborators like the University at Albany’s Center for Emerging Artificial Intelligence Systems. 

The IBM Research prototype has evolved into an enterprise-grade product for use in IBM Z, LinuxONE and Power systems. Today, the Spyre Accelerator is a commercial system-on-a-chip with 32 individual accelerator cores and 25.6 billion transistors. Produced using 5nm node technology, each Spyre is mounted on a 75-watt PCIe card, which makes it possible to cluster up to 48 cards in an IBM Z or LinuxONE system or 16 cards in an IBM Power system to scale AI capabilities.

“One of our key priorities has been advancing infrastructure to meet the demands of new and emerging AI workloads,” said Barry Baker, COO, IBM Infrastructure & GM, IBM Systems. “With the Spyre Accelerator, we’re extending the capabilities of our systems to support multi-model AI – including generative and agentic AI. This innovation positions clients to scale their AI-enabled mission-critical workloads with uncompromising security, resilience, and efficiency, while unlocking the value of their enterprise data.”

“We launched the IBM Research AI Hardware Center in 2019 with a mission to meet the rising computational demands of AI, even before the surge in LLMs and AI models we’ve recently seen,” said Mukesh Khare, GM of IBM Semiconductors and VP of Hybrid Cloud, IBM. “Now, amid increasing demand for advanced AI capabilities, we’re proud to see the first chip from the Center enter commercialization, designed to deliver improved performance and productivity to IBM’s mainframe and server clients.”

For IBM clients, Spyre Accelerators offer fast, secured processing with on-prem AI acceleration. This marks a significant milestone, allowing businesses to leverage AI at scale while keeping data on IBM Z, LinuxONE and Power systems. In mainframe systems, coupled with the Telum II processor for IBM Z and LinuxONE, Spyre offers enhanced security, low latency, and high transaction rate processing power. Leveraging this advanced hardware and software stack, businesses can use Spyre to scale multiple AI models to power predictive use cases such as advanced fraud detection and retail automation.

On IBM Power-based servers, Spyre customers can leverage a catalog of AI services, enabling end-to-end AI for enterprise workflows. Clients can install the AI services from the catalog with just one click.¹  Spyre Accelerator for Power, combined with an on-chip accelerator (MMA), also accelerates data conversion for generative AI to deliver high throughput for deep process integrations. Additionally, with a prompt size of 128, it enables the ingestion of more than 8 million documents for knowledge base integration in an hour². This performance, combined with the IBM software stack, security, scalability, and energy efficiency, supports clients on their journey to integrating generative AI frameworks into their enterprise workloads.

To learn more about the IBM Spyre Accelerator, visit http://www.ibm.com/solutions/ai-accelerator.

Additional resources:

• IBM LinuxONE blog
• IBM Power blog
• IBM Research blog
• IBM Z blog

About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain a competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media Contacts
Willa Hahn, willa.hahn@ibm.com
Chase Skinner, Chase.Skinner@ibm.com

¹ AI service of the IBM-supported catalog is delivered as one or a set of containers that can be deployed with a single deployment command. The provided UI for the catalog executes such commands in the backend based on a single click within the UI page of the respective AI service.
² Based upon internal testing running 1M unit data set with prompt size 128, batch size 128 using 1-card container.  Individual results may vary based on workload size, use of storage subsystems and other conditions.

Metabolon’s best-in-class metabolomics leadership accelerates as metabolomics becomes a standard inclusion in global multiomics studies

MORRISVILLE, N.C., Oct. 7, 2025 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that its metabolomics services have now been cited in more than 4,000 peer-reviewed publications, far more than any other metabolomics provider in the life sciences industry. 

Publications referencing Metabolon’s platform and results have appeared in many of the world’s most respected journals, including Nature, Nature Medicine, Nature Genetics, Cell, and the Proceedings of the National Academy of Sciences (PNAS). These peer-reviewed citations underscore the increasing recognition of metabolomics as an essential component of multiomics research. 

“Metabolomics has become a standard inclusion in cutting-edge multiomics research. We’re seeing this across all customer segments globally,” said Ro Hastie, Metabolon CEO. “The growth of Metabolon’s wide-ranging citations underscores metabolomics’ transformative impact across diverse scientific fields. Studies without metabolomics risk missing key biological insights, while Metabolon’s Level 1 metabolomics library and services provide the most comprehensive foundation for global multiomics research.”

Supported by an ISO 9001 and CAP-accredited lab and fully integrated commercial and scientific teams, Metabolon meets enterprise-grade compliance standards while demonstrating proven demand. Metabolon has delivered more than 15,000 studies worldwide in partnership with leading pharmaceutical, biotech, academic, and government institutions. With a robust infrastructure and established reputation, Metabolon is advancing precision health worldwide with collaborations spanning biopharma, population health, consumer goods, agriculture, wellness, and research.

For more information, please visit:

• Metabolon’s Global Discovery Panel:https://www.metabolon.com/resources/ebooks/global-panel/
• Metabolon’s Guide to Multiomics:https://www.metabolon.com/resources/ebooks/guide-to-multiomics/

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

About Metabolon 
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 25 years, 15,000+ projects, 4,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technological, and bioinformatics techniques. Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

Logo – https://laotiantimes.com/wp-content/uploads/2025/10/metabolon_inc_logo.jpg

Showcasing at AAO 2025:

• NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography angiography (OCT-A) with ZEISS CIRRUS AngioPlex^® with noninvasive imaging of the retinal and choroidal vasculature; now with 510k clearance and CE approval, ICGA for CLARUS^® 700 offers FA + ICG simultaneous capture.
• OPTIMIZED RETINAL SURGICAL EXPERIENCE: Announcing updates to DORC instruments to expand surgeons’ options, including new gauges added to the range of subretinal injection cannulae and a new Midfield endoillumination light probe with directed light; updated CALLISTO eye^® software on the ZEISS ARTEVO 850 and ZEISS ARTEVO 750 supports increased visualization.
• IMPROVED GLAUCOMA MANAGEMENT FOR CATARACT PATIENTS: Demonstrating a fully integrated diagnostic and treatment solution for managing comorbid cataract/glaucoma patients to support more efficient and confident decision making.
• ENHANCED OPHTHALMIC RESEARCH AND COLLABORATION: Featuring the AI-ready ZEISS Research Data Platform (RDP), which can empower retina specialists to transform their clinical hypotheses into measurable outcomes; previewing the next evolution of browser-based digital data management which aggregates clinical data at scale, powers advanced analytics, and enables seamless collaboration across eye care professionals for more personalized patient care delivery.
• REFRACTIVE INDUSTRY MILESTONE: Celebrating more than 12 million eyes treated with ZEISS SMILE and ZEISS SMILE pro.

JENA, Germany and DUBLIN, Calif., Oct. 7, 2025 /PRNewswire/ — ZEISS Medical Technology will showcase its latest enhancements in ophthalmic visualization and digital workflow innovation at the American Academy of Ophthalmology (AAO) conference from Oct. 18 – 20, 2025, in Orlando, FL.

Carl_Zeiss_Meditec_AG_New_Midfield_endoillumination_light_probe_with_directed_light

“ZEISS continues to be at the forefront of optical and digital innovation, advancing our clinical workflows to be more efficient and empowering for doctors and surgeons around the world to deliver more precise and personalized care for their patients,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology.

“We’re delivering important enhancements to our expanding portfolio across ZEISS and DORC solutions to meet the growing needs of ophthalmologists worldwide,” said PT Cheong, Head of Global Sales for Ophthalmology, ZEISS Medical Technology. “From diagnostics to surgery and post-op management, our advanced technology solutions support more confident, personalized patient care.”

Advancing visualization and efficiency throughout the spectrum of retinal care

The ZEISS Retina Workflow offers a digitally connected solution from diagnostics through surgery and post-op care, supporting healthcare professionals in advancing retinal care with enhanced data continuity, procedural efficiency, and clinical decision-making across the retina care pathway. 

At AAO, ZEISS will showcase multiple diagnostic enhancements supporting improved decision making and pathology detection through gold-standard imaging technology. Now with 510k clearance and CE approval¹, the CLARUS^® 700 with ICGA provides high-resolution early-phase to late-phase ultra-widefield imaging. New features include standalone ICG, simultaneous FA-ICG capture, and an added movie mode for all angiography modalities: standalone FA, standalone ICG, and simultaneous FA-ICG. These advancements underscore ZEISS’s commitment to delivering cutting-edge solutions that enhance clinical outcomes and streamline the diagnostic process for healthcare professionals.

Additionally, this year marks the 100-year anniversary of advancements in ZEISS fundus imaging. In 1926, ZEISS and Johan Nordenson released the first commercially available fundus camera, laying the foundation for a century of innovation in ocular imaging technology.

ZEISS will also showcase its latest in OCT technology, providing enhanced details and insights to assist eyecare practitioners when examining patients and managing diseases. The implementation of best practices is helpful to maximize the clinical utility of OCT-A. In recognition of this, ZEISS has released OCT-A Simplified, a step-by-step eBook by Ricardo Luz Leitão Guerra, MD, MSc, FICO. The guidebook makes OCT-A more accessible to eyecare practitioners, covering image acquisition, analysis, and interpretation providing practical insights clinicians can apply immediately in clinical decision-making. Copies of the OCT-A Simplified ebook will be available at AAO at the ZEISS booth #2261.

ZEISS continues to offer the latest in OCT solutions, most recently gaining CE mark for CIRRUS PathFinder, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician’s patient care workflow with OCT interpretation assistance, supporting improved surgical planning, particularly for high-volume clinics.

To further optimize the surgical experience for vitreoretinal surgeons, ZEISS will showcase new updates² to its DORC instrument portfolio within the ZEISS Retinal Workflow.

• New gauges added to the company’s range of subretinal injection cannulae: 25G and 27G.³ The subretinal cannulas are designed for injection of fluids and/or gases into subretinal space and feature a 41G extendible tip for a smooth and uninterrupted sliding motion. The range is compatible with EVA NEXUS’s INICIO micro-injection system. EVA NEXUS is the only system cleared by the FDA for subretinal injection in the U.S.
• The new Midfield endoillumination light probe⁴ with directed light. The light probe provides a homogeneous field of illumination of about 60° with sharply defined edges, enabling surgeons to effectively distinguish between different media, such as vitreous, BSS and air. The new light probe is also suitable for trans-scleral illumination and comes with a trans-scleral depressor as standard. The probe is available in three gauges: 23G, 25G and 27G.⁵
• The DORC EVA NEXUS^™ platform, uniquely suited to address both retina and cataract surgery, is now available with angled EquiPhaco designed for optimal irrigation flow. EquiPhaco, combined with EVA NEXUS SMART IOP^™, allows for a more stable, lower anterior chamber pressure during procedures.

Lastly, ZEISS will showcase its updated CALLISTO eye^® software for ZEISS ARTEVO 750 and ZEISS ARTEVO 850, allowing for visualization of retinal structures on the 3D screen of the ZEISS ARTEVO 850 with up to 30% higher magnification⁶. Advanced camera settings, including automatic exposure control, provide customization of the visualization experience to a surgeon’s individual preferences. In addition, the software update now also offers reference image matching for toric IOL implantations in either the eyepiece of the ZEISS ARTEVO 750 or the 3D monitor of the ZEISS ARTEVO 850 as well as optional 3D recording on the ZEISS ARTEVO 850.

Improved efficiency for surgery planning through integrated glaucoma support

ZEISS diagnostic and digital solutions integrated into surgical ophthalmic workflows can help surgeons visualize more, connect insights across a workflow, and make data-driven decisions, including earlier detection of eye conditions that may affect surgical planning and outcomes. At AAO, ZEISS will demonstrate a fully integrated solution connecting cataract and glaucoma workflows to support more efficient and confident decision making.

Glaucoma is the most common comorbidity in cataract surgery. According to a recent study⁷, around 20% of patients who undergo cataract procedures also have glaucoma or ocular hypertension. ZEISS offers integrated diagnostic and therapeutic solutions to support earlier detection and management of glaucoma in cataract patients, helping to improve long-term outcomes of cataract surgery. Devices including the ZEISS SL 800, CLARUS^®, CIRRUS^® OCT, ARTEVO^® 750, and VISULAS^® are shared across the cataract and glaucoma workflows and seamlessly connected via FORUM^® for complete data continuity.

Empowering the future of ophthalmology with enhanced research and collaboration tools

At AAO, the company will feature the ZEISS Research Data Platform (RDP), a secure, cloud-based, AI-driven solution designed for multi-center research and real-world clinical evidence, enabling retina specialists to translate their clinical hypotheses into measurable outcomes. With built-in support for AI algorithm training and biomarker generation, the ZEISS RDP allows researchers to harness complex data and drive innovation without compromising on compliance or collaboration.

ZEISS will also preview the next evolution of browser-based digital data management solution that seamlessly integrates with EMR systems to aggregate essential medical data and can connect diagnostic data from ZEISS and non-ZEISS devices. The solution provides actionable clinical insights through color-coded alerts, trend analysis for OCT and Visual Field data, and interactive analyses. Offered in flexible subscription packages, providers can select the configuration that fits their practice needs.

Celebrating continued excellence in refractive innovation

ZEISS continues to extend its global, refractive momentum with the celebration of more than 12 million eyes treated with SMILE^® and SMILE^® pro, reflecting the growing international adoption of safe and effective lenticule extraction solutions. ZEISS SMILE and ZEISS SMILE pro continue to be leading solutions trusted by surgeons for the technology’s proven reliability and effective treatment with the VisuMax^® and VISUMAX^® 800 from ZEISS.

ZEISS will showcase its latest offerings and new innovations at the American Academy of Ophthalmology (AAO) conference from Oct. 18 – 20, 2025, in Orlando, FL, at booth #2261. 

For more information, visit www.zeiss.com/med. 

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. 

Contact for investors
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.meditec@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications
Ophthalmology, Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

www.zeiss.com/newsroom

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

Carl_Zeiss_Meditec_AG_New_gauges_for_subretinal_injection_cannulae

Carl_Zeiss_Meditec_AG_ZEISS_AngioPlex_OCT_Angiography

Carl_Zeiss_Meditec_AG_CLARUS_700_with_ICGA_modality

Carl_Zeiss_Meditec_AG_Celebrating_more_than_12_million_eyes_treated_with_SMILE